Loading...
•
Jun 30, 2021
uniQure Q2 2021 Earnings Report
uniQure reported financial results for the second quarter of 2021 and highlighted recent progress across its business.
Key Takeaways
uniQure had a productive second quarter, marked by the closing of a global commercial licensing agreement with CSL Behring in hemophilia B and the presentation of positive 52-week data from the HOPE-B pivotal study. The company also disclosed four new research programs and announced the acquisition of Corlieve Therapeutics.
Expanded gene therapy pipeline with four new research programs and announced acquisition of Corlieve Therapeutics
Presented positive 52-week data from HOPE-B pivotal study demonstrating sustained increases in Factor IX (FIX) levels with mean FIX activity of 41.5 percent of normal and significant reductions in bleeding events
Completed its global commercialization and license transaction with CSL Behring for hemophilia B gene therapy program
Initiated patient enrollment in second dose cohort of Phase I/II clinical trial of AMT-130 for Huntington’s disease, with initiation of a European Phase Ib/II clinical trial expected in second half of 2021
Revenue by Segment
Forward Guidance
uniQure expects to continue its progress across all programs, including availability of 78-week data from the HOPE-B study, initiating patient enrollment for its open-label European study of AMT-130 in Huntington’s disease, and announcing initial data on the first four randomized Huntington’s disease patients in the ongoing U.S. Phase I/II study.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...